Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation

Matthew J. Sikora, Viktoriya Strumba, Marc E Lippman, Michael D. Johnson, James M. Rae

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Despite the success of the aromatase inhibitors (AIs) in treating estrogen receptor positive breast cancer, 15-20 % of patients receiving adjuvant AIs will relapse within 5-10 years of treatment initiation. Long-term estrogen deprivation (LTED) of breast cancer cells in culture mimics AI-induced estrogen depletion to dissect mechanisms of AI resistance. However, we hypothesized that a subset of patients receiving AI therapy may maintain low circulating concentrations of estrogens that influence the development of endocrine resistance. We expanded established LTED models to account for incomplete suppression of estrogen synthesis during AI therapy. MCF-7 cells were grown in medium with charcoal-stripped serum supplemented with defined concentrations of 17b-estradiol (E2) or the estrogenic androgen metabolite 5a-androstane-3b, 17b-diol (3bAdiol), an endogenous selective estrogen receptor modulator. Cells were selected in concentrations of E2 or 3bAdiol that induce 10 or 90 percent of maximal proliferation (EC10 and EC90, respectively), or estrogen deprived. Estrogen independence was evaluated during selection by assessing cell growth in the absence or presence of E2 or 3bAdiol. Following>7 months of selection, estrogen independence developed in estrogen-deprived cells and EC10-selected cells. Functional analyses demonstrated that estrogen-deprived and EC10-selected cells developed estrogen independence via unique mechanisms, ERa-independent and dependent, respectively. Estrogenindependent proliferation in EC10-selected cells could be blocked by kinase inhibitors. However, these cells were resistant to kinase inhibition in the presence of low steroid concentrations. These data demonstrate that further understanding of the total estrogen environment in patients on AI therapy who experience recurrence is necessary to effectively treat endocrine-resistant disease.

Original languageEnglish
Pages (from-to)1027-1039
Number of pages13
JournalBreast Cancer Research and Treatment
Volume134
Issue number3
DOIs
StatePublished - Aug 1 2012

Fingerprint

Estrogens
Aromatase Inhibitors
Breast Neoplasms
Growth
Phosphotransferases
Endocrine System Diseases
Selective Estrogen Receptor Modulators
Recurrence
Charcoal
MCF-7 Cells
Therapeutics
Estrogen Receptors
Androgens
Estradiol
Cell Culture Techniques
Steroids
Serum

Keywords

  • Androgen
  • Aromatase inhibitor
  • Breast cancer
  • Endocrine resistance
  • Estrogen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. / Sikora, Matthew J.; Strumba, Viktoriya; Lippman, Marc E; Johnson, Michael D.; Rae, James M.

In: Breast Cancer Research and Treatment, Vol. 134, No. 3, 01.08.2012, p. 1027-1039.

Research output: Contribution to journalArticle

Sikora, Matthew J. ; Strumba, Viktoriya ; Lippman, Marc E ; Johnson, Michael D. ; Rae, James M. / Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. In: Breast Cancer Research and Treatment. 2012 ; Vol. 134, No. 3. pp. 1027-1039.
@article{af7094e6ab464978855a8af0a60c4e75,
title = "Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation",
abstract = "Despite the success of the aromatase inhibitors (AIs) in treating estrogen receptor positive breast cancer, 15-20 {\%} of patients receiving adjuvant AIs will relapse within 5-10 years of treatment initiation. Long-term estrogen deprivation (LTED) of breast cancer cells in culture mimics AI-induced estrogen depletion to dissect mechanisms of AI resistance. However, we hypothesized that a subset of patients receiving AI therapy may maintain low circulating concentrations of estrogens that influence the development of endocrine resistance. We expanded established LTED models to account for incomplete suppression of estrogen synthesis during AI therapy. MCF-7 cells were grown in medium with charcoal-stripped serum supplemented with defined concentrations of 17b-estradiol (E2) or the estrogenic androgen metabolite 5a-androstane-3b, 17b-diol (3bAdiol), an endogenous selective estrogen receptor modulator. Cells were selected in concentrations of E2 or 3bAdiol that induce 10 or 90 percent of maximal proliferation (EC10 and EC90, respectively), or estrogen deprived. Estrogen independence was evaluated during selection by assessing cell growth in the absence or presence of E2 or 3bAdiol. Following>7 months of selection, estrogen independence developed in estrogen-deprived cells and EC10-selected cells. Functional analyses demonstrated that estrogen-deprived and EC10-selected cells developed estrogen independence via unique mechanisms, ERa-independent and dependent, respectively. Estrogenindependent proliferation in EC10-selected cells could be blocked by kinase inhibitors. However, these cells were resistant to kinase inhibition in the presence of low steroid concentrations. These data demonstrate that further understanding of the total estrogen environment in patients on AI therapy who experience recurrence is necessary to effectively treat endocrine-resistant disease.",
keywords = "Androgen, Aromatase inhibitor, Breast cancer, Endocrine resistance, Estrogen",
author = "Sikora, {Matthew J.} and Viktoriya Strumba and Lippman, {Marc E} and Johnson, {Michael D.} and Rae, {James M.}",
year = "2012",
month = "8",
day = "1",
doi = "10.1007/s10549-012-2032-6",
language = "English",
volume = "134",
pages = "1027--1039",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation

AU - Sikora, Matthew J.

AU - Strumba, Viktoriya

AU - Lippman, Marc E

AU - Johnson, Michael D.

AU - Rae, James M.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Despite the success of the aromatase inhibitors (AIs) in treating estrogen receptor positive breast cancer, 15-20 % of patients receiving adjuvant AIs will relapse within 5-10 years of treatment initiation. Long-term estrogen deprivation (LTED) of breast cancer cells in culture mimics AI-induced estrogen depletion to dissect mechanisms of AI resistance. However, we hypothesized that a subset of patients receiving AI therapy may maintain low circulating concentrations of estrogens that influence the development of endocrine resistance. We expanded established LTED models to account for incomplete suppression of estrogen synthesis during AI therapy. MCF-7 cells were grown in medium with charcoal-stripped serum supplemented with defined concentrations of 17b-estradiol (E2) or the estrogenic androgen metabolite 5a-androstane-3b, 17b-diol (3bAdiol), an endogenous selective estrogen receptor modulator. Cells were selected in concentrations of E2 or 3bAdiol that induce 10 or 90 percent of maximal proliferation (EC10 and EC90, respectively), or estrogen deprived. Estrogen independence was evaluated during selection by assessing cell growth in the absence or presence of E2 or 3bAdiol. Following>7 months of selection, estrogen independence developed in estrogen-deprived cells and EC10-selected cells. Functional analyses demonstrated that estrogen-deprived and EC10-selected cells developed estrogen independence via unique mechanisms, ERa-independent and dependent, respectively. Estrogenindependent proliferation in EC10-selected cells could be blocked by kinase inhibitors. However, these cells were resistant to kinase inhibition in the presence of low steroid concentrations. These data demonstrate that further understanding of the total estrogen environment in patients on AI therapy who experience recurrence is necessary to effectively treat endocrine-resistant disease.

AB - Despite the success of the aromatase inhibitors (AIs) in treating estrogen receptor positive breast cancer, 15-20 % of patients receiving adjuvant AIs will relapse within 5-10 years of treatment initiation. Long-term estrogen deprivation (LTED) of breast cancer cells in culture mimics AI-induced estrogen depletion to dissect mechanisms of AI resistance. However, we hypothesized that a subset of patients receiving AI therapy may maintain low circulating concentrations of estrogens that influence the development of endocrine resistance. We expanded established LTED models to account for incomplete suppression of estrogen synthesis during AI therapy. MCF-7 cells were grown in medium with charcoal-stripped serum supplemented with defined concentrations of 17b-estradiol (E2) or the estrogenic androgen metabolite 5a-androstane-3b, 17b-diol (3bAdiol), an endogenous selective estrogen receptor modulator. Cells were selected in concentrations of E2 or 3bAdiol that induce 10 or 90 percent of maximal proliferation (EC10 and EC90, respectively), or estrogen deprived. Estrogen independence was evaluated during selection by assessing cell growth in the absence or presence of E2 or 3bAdiol. Following>7 months of selection, estrogen independence developed in estrogen-deprived cells and EC10-selected cells. Functional analyses demonstrated that estrogen-deprived and EC10-selected cells developed estrogen independence via unique mechanisms, ERa-independent and dependent, respectively. Estrogenindependent proliferation in EC10-selected cells could be blocked by kinase inhibitors. However, these cells were resistant to kinase inhibition in the presence of low steroid concentrations. These data demonstrate that further understanding of the total estrogen environment in patients on AI therapy who experience recurrence is necessary to effectively treat endocrine-resistant disease.

KW - Androgen

KW - Aromatase inhibitor

KW - Breast cancer

KW - Endocrine resistance

KW - Estrogen

UR - http://www.scopus.com/inward/record.url?scp=84868200933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868200933&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2032-6

DO - 10.1007/s10549-012-2032-6

M3 - Article

C2 - 22456984

AN - SCOPUS:84868200933

VL - 134

SP - 1027

EP - 1039

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -